Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPOTLIGHT-204 intralesional BO-112 in resectable primary basal cell carcinoma
MOH_2024-03-13_013305Phase 2Recruiting
- Sponsor
- Highlight Therapeutics
- Start
- Mar 2024
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of nanoplexed poly I:C in basal cell carcinoma (BCC) (2 arms), sponsored by Highlight Therapeutics. Primary endpoints: Visual assessment of lesion efficacy at approximately 6 months and Pathologic tumor persistence after surgical excision at approximately 6 months. Started Mar 2024; status: recruiting.
02
Drugs
nanoplexed poly I:C
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on MOH_2024-03-13_013305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-03-13_013305.